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The cytokines, main players of the chronic inflammation
progression leading to serious diseases such as diabetes or
cancer, represent a target for better clinical prognosis
and innovative therapeutic strategies. To investigate the
immunopathogenetic progression of these diseases, the
evaluation of serum cytokines profiles made of many
different proteins is much more informative than single
protein measurements. We developed a Clinical Data
Mining Software to collect cytokine profiles evaluated on
healthy subjects and patients by multiplex immunoassays
also annotated with their clinical and laboratory data, to
compare patient profiles by statistical tools and to evalu-
ate their disease progression.
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Introduction
The progressive increase in electronically stored clinical data
is opening the possibility of carrying out large-scale studies
aimed to discover correlations between new research data
and related diseases. For these reasons, many relational data-
bases have implemented data mining techniques (Harrison,
2008). Data mining has been described as the ‘extraction of
implicit, previously unknown and potentially useful infor-
mation’, such as associations and correlations between data
elements from large repositories of data (Lee and Siau,
2001). Data mining techniques include methods to group
data elements that have similar features (association rules,
clustering etc.) and methods to determine predictive relation-
ships between groups of data elements (classification and
neural network) (Hand, 2007). An overview of open-source
data mining tools is provided by Zupan and Demsar (Zupan
and Demsar, 2008) explaining that there are diverse data
mining methods and user interfaces. Moreover, they demon-
strate that this field and its tools are ready to be fully
exploited in biomedical research.
However, the scientific community needs clinical labora-
tory databases to collect medical data related to diseases pro-
gression and therapy response. In the last years, particular
attention has been focused on the protein class comprising
cytokines, chemokines and growth factors, because they play
a crucial role in promoting angiogenesis, metastasis and sub-
version of adaptive immunity. On the whole, we define with
the term ‘cytokinome’ the totality of these proteins and their
interactions in and around biological cells. In particular, these
proteins are involved in cancer-related chronic inflammation
and can represent a target for innovative clinical prognosis
useful for therapeutic and clinical strategies (Mantovani and
Pierotti, 2008; Mantovani et al., 2008). Since the control of
cytokine production is highly complex and multifactorial,
their effects are mediated through multiple regulatory net-
works. The intricate complexity of these networks clearly
conceals the role that a single cytokine may play in the patho-
genesis of the disease. Therefore, it is more informative to
investigate the immunopathogenesis of a disease process by
analyzing a multiple panel of cytokines (Costantini et al.,
2009). Utilizing a bead-based broad-spectrum multiplex
immunoassay, it is possible not only to evaluate the serum
levels of those cytokines ensemble that effectively correlate
with the progression of the disease activity but also to define
the immunomodulatory effects of a therapy even after months
of treatment (Sato et al., 2009; Ozturk et al., 2009; Capone
et al., 2010). This indicates that the definition and evaluation
of a human cytokinome represents an important future tool to
analyze the interaction network of cytokines both in healthy
individuals and in patients affected by different diseases. In
fact, it will permit one to understand and investigate how the
regression of a chronic inflammation process, by acting on the
cellular populations of cytokines, can block the progression
of a cancer and, therefore, it can be a useful prognostic and
diagnostic tool for clinicians.
For these reasons, a portal with user-friendly interfaces,
which can be used both by physicians and researchers not
only to collect and to correlate clinical data and serum levels
of cytokines but also to know quickly what cytokines, che-
mokines or growth factors are significant in the progression
state of a given disease, represents an important and useful
tool for clinical prognosis and therapy studies.
In this work, we have developed software to collect clini-
cal data and serum levels of many cytokines, chemokines
and growth factors evaluated on healthy subjects and patients
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affected by different diseases using multiplex immunoassays.
Moreover, some statistical tools were implemented to corre-
late significatively clinical and experimental data. At present,
we focused our attention on chronic hepatitis C and hepato-
carcinoma (HCC) diseases. However, our software can be
easily upgraded for other chronic diseases. We are also
developing a routine to quickly compare standardized cytoki-
nome profile of a patient against a whole data bank that col-
lects cytokinome data from some different diseases. This
routine will be able to support a reliable diagnosis/prognosis
of patients with a progressive disease clinically still silent.
Of course, the more data there are in the data bank, the more
reliable will be the result. We think that this type of tool is
essential for a predictive medicine. Our portal is named
CDMS (Clinical Data Mining Software) and is accessible at
the URL: http://www.cro-m.eu/CDMS/.
Methods
CDMS was developed using Web server Apache/2.2.11,
MySQL version 5.0.75, PHP/5.2.6-3 Ubuntu version 9.04
and phpMyAdmin version 3.1.2 deb1 Ubuntu 0.2. It is a
web-oriented software that was realized using the scripting
language PHP, the JavaScript technology for dynamic con-
tents, the markup language HTML and style sheet CSS 2.0.
For most of the statistical analysis, the aggregate functions of
MySQL were used. Moreover, we developed specific PHP
scripts for the t-test formula, correlation formula and related
graphs. Block diagram of portal functionality is shown in
Fig. 1.
Description of CDMS portal
CDMS software is used for the collection of clinical data
and cytokine concentrations evaluated by broad-spectrum
bead-based multiplex immunoassay in healthy donors and in
patients with chronic hepatitis C and HCC. In this portal,
there are some statistical tools to analyse both clinical data
and serum levels of cytokines and to visualize these data
through graphs. CDMS was developed using the web-
oriented typology that permits (i) the consultation, updating
and processing of all information related to each patient in
real time and in remote modality, (ii) the information sharing
between authorized users and (iii) data security.
CDMS allows certified users to access some of its services
on the basis of their privileges. In detail, homepage for the
administrator presents users administration, patient adminis-
tration and statistical analysis sections. Physicians and
Researchers can access the patient administration and statisti-
cal analysis sections, and all other authorized figures can
access only statistical analysis section. In the patient adminis-
tration section, there are case histories of patients with infor-
mation related to their diagnosis, biological analyses as well
as clinical data, and cytokine evaluations. In particular, in
this section, one can insert 122 biological data for each
patient (Table I) and the concentrations of 50 cytokines com-
prising 20 interleukins, 12 chemokines, 2 interferons, 10
growth factors and other 6 proteins (Table II). In detail, these
cytokines were chosen because they are present in two com-
mercial kits (BioRad Lab., Inc.) used to evaluate the cyto-
kines serum levels in blood samples from healthy subjects
and patients with chronic hepatitis C or HCC by using
multiplex immunoassays. In fact, many of these molecules
(i.e. IL-8, CXCL9, CXCL10) are the most representative in
these two diseases. However, CDMS can be easily upgraded
and, therefore, it is possible to insert both other chronic dis-
eases and other proteins. Moreover, for the same patients, it
is possible to insert the cytokine profiles evaluated at differ-
ent times to compare and evaluate results at different stages
of the disease.
In the statistical analysis section, the user can select the
disease, filter the patients on the basis of gender, age and
experiment date and select the most appropriate tool to
perform the statistical analysis. In particular, we have
implemented: (i) median, mean, variance, standard deviation,
min and max values for the selected protein (Supplementary
data, Fig. 1SA); (ii) t-test value related to the comparison
between cytokine concentrations in control group and
patients; (iii) Pearson correlation between different cyto-
kines with related graph (Supplementary data, Fig. 1SB);
(iv) Pearson correlation between each cytokine and some
clinical data (i.e. tumor size) with related graph.
The system administrator can access to the users adminis-
tration section for all the registration procedures of new users
assessing ‘username and password’ and mailing them to
users. The password will be created in random modality by
using the MD5 algorithm (Rivest, 1991) and modifiable at
user’s request. All the authorized users can access the glos-
sary section for information and details related to biological
and clinical meaning of cytokines.
Conclusions
The relationships between chronic inflammation and pro-
gression of diseases represent a topic of great interest but one
that is not yet used for a reliable predictive medicine because
of its inherent complexity due to the very large amount of
data to take into account. In fact, it is well known that the
principal players of the chronic inflammatory processes are
the cytokines, chemokines and growth factors but it is still
difficult to analyze the whole spectrum of their progression
in time without an adequate informative support. Therefore,
CDMS represents, to the best of our knowledge, the first
‘user-friendly’ tool that can be used by researchers as well as
physicians and clinicians to significatively correlate clinical
data and cytokine profiles and to identify what cytokines can
be significant for the examined disease at a given time. In
particular, we have used CDMS in our recent work (Capone
et al., 2010) where the HCC was chosen as a studying
model. In fact, the serum levels of 50 different cytokines,
chemokines and growth factors were evaluated in patients
affected by HCC with chronic HCV-related hepatitis and
liver cirrhosis using a bead-based broad-spectrum multiplex
immunoassay. Both clinical data and cytokines serum levels
of all the patients and of healthy subjects group, included as
controls, are collected in CDMS. Using the available statisti-
cal tools, we have identified the cyto-chemokines pattern
involved in the chronic inflammation processes versus HCC
(i.e. IL-1a, IL-6, IL-8, IL-12p40, GM-CSF, CCL27, CXCL1,
CXCL9, CXCL10, CXCL12, b-NGF). Moreover, it has been
possible by CDMS to correlate the cytokine serum levels
with the clinical data and to verify that IL-8 correlates sig-
nificantly with large tumor size (.5 cm), and it can be used
both as a useful marker of tumor invasiveness and as an
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independent prognostic factor for HCC patients (Capone
et al., 2010).
Therefore, this tool can be a useful support to develop a
reliable predictive medicine. Moreover, we are planning to
open the data set to other diseases and implement other stat-
istical tools and classification methods to improve or discover
new predictive relationships among data groups.
Supplementary data
Supplementary data are available at PEDS online.
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Table I. List of data for patient administration section
Personal data and diagnosis
Inserting date Id diagnosis Diagnosis Etiology
Name Id patient Therapy type State (live/dead)
Surname Diagnosis date Chronic
hepatitis
Motivation dead
Gender Operation date Cirrhosis Clinical
presentation
Place of birth Last control date Child Type
Date of birth Follow-up No cancers Side
Blood Previous
treatment date
Cancer place Tumor size
Rh-Positive Previous
treatment
Cancer
dimension
Lymph nodal
status
Building Treatment Metastasis Cellular type
Healthy Treatment date TNM Sarcomatoid
variant
Notes Surgical
technique
Grading Diagnosis note
Clinical data
AbT Got CEA MON
AbTPO GPT CIC Na
Ac. Urico HAV Cl NEU
aFP HBV Col.Tot PLT
Albumin HCV Colinesterase PM
ALP HGB Cortisol PRL
ALT IgA Free cortisol Proteins
Amilase IgG CPK PT
Antibodies to
adrenal cortex
Igk Creatinine TE
Antibodies to
pituitary
Igl EOS PTT
AST IgM Estradiol RBC
Azotemy IL-6 Fe mc sIL2-R
b2M INR FOS.
ALCALINE
One
BAS k/l FSH HCV title
Bilirubin Tot. k/l fT3p TNFa
Bilirubin Dir LDH fT4p Tryglicerides
C3 LH Genotype HCV BOSIS
C4 LUC gGT TSH
CA LYN Glycemia WBC
CA19-9 Mg
Table II. List of Cytokines
Interleukins IL-1a, IL-1b, IL-1ra, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15,
IL-16, IL-17, IL-18
Chemokines MCP-1, MCP-3, MIF, MIP-1a, MIP-1b, RANTES,
Eoxatin, CTACK, CXCL1, CXCL9, CXCL10, CXCL12
Growth
factors
Basis FGF, b-NGF, G-CSF, GM-CSF, HGF, M-CSF,
PDGF-bb, SCF, SCGF-b, VEGF
Interferons INF-a2, INF-g
Other
proteins
LIF, ICAM-1, TNF-a, TNF-b, TRAIL, VCAM-1
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